IP Library Granted Patent US 8,153,390
Granted Patent B2
US 8,153,390 · App. 12/773,797 · Granted Apr 10, 2012

FRET-based binding assay

Assignee: Roche Palo Alto LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,153,390
App. No.
12/773,797
Granted
Apr 10, 2012
Kind
B2
Abstract

The present invention provides for an assay that identifies kinase inhibitors by employing fluorescence resonance energy transfer in a competition binding approach.

Claims (8)

1. A method of screening for a substance that may be acting as a kinase inhibitor, said method comprising the steps of:

a) providing a kinase enzyme that is fused at its C-terminus with an amino acid sequence that allows covalent attachment of biotin wherein said amino acid sequence comprises SEQ ID NO:1;

b) providing streptavidin that is labeled with a fluorescent donor moiety or a fluorescent acceptor moiety;

c) providing a known kinase inhibitor wherein said known kinase inhibitor is labeled with a fluorescent acceptor moiety if said streptavidin in step b) is labeled with a fluorescent donor moiety, and wherein said known kinase inhibitor is labeled with a fluorescent donor moiety if said streptavidin in step b) is labeled with a fluorescent acceptor moiety;

d) incubating said kinase enzyme, said streptavidin and said known kinase inhibitor in a reaction mixture in either the presence or absence of said substance;

e) exposing the reaction mixture to light that allows fluorescence resonance energy transfer to take place and measuring fluorescence emission from the reaction mixture; wherein if the fluorescence emission measurement from the reaction mixture in the presence of said substance is different than the fluorescent emission measurement from the mixture in the absence of said substance, said substance is acting as a kinase inhibitor.

2. The method of claim 1 wherein the covalent attachment of biotin occurs intracellularly.

3. The method of claim 1 wherein the covalent attachment of biotin occurs in vitro.

Continuity (2)
Provisional Application 61175692 · May 5, 2009
Related Publication 20100285503A1 · Nov 11, 2010